1. A trial of RIT-4237 rotavirus vaccine in 1-month-old infants
- Author
-
J. Deutsch, C.-H. Kunz, I. D. Mutz, D. E. Teuwen, and F. Krainer
- Subjects
Rotavirus ,Pediatrics ,medicine.medical_specialty ,Reoviridae ,Placebo ,medicine.disease_cause ,Vaccines, Attenuated ,Rotavirus Infections ,Young infants ,Double blind ,Placebos ,Random Allocation ,fluids and secretions ,Double-Blind Method ,Medicine ,Humans ,Clinical Trials as Topic ,biology ,business.industry ,Infant, Newborn ,Rotavirus Vaccines ,Infant ,Viral Vaccines ,biology.organism_classification ,Rotavirus vaccine ,Gastroenteritis ,Antibody response ,Immunization ,Immunoglobulin M ,Pediatrics, Perinatology and Child Health ,Immunology ,Antibody Formation ,business - Abstract
In a double blind placebo-controlled study rotavirus vaccine RIT 4237 was offered to young infants after the fourth week of life. The vaccine was very well tolerated. Fifty-seven out of 100 vaccine recipients and 10 out of 103 placebo recipients developed rotavirus-IgM-antibodies during the 1 month follow-up period. During a 6 month follow-up, stool samples from 2 out of 12 vaccinees and from 5 out of 12 placebo recipients contained rotavirus.
- Published
- 1989